NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $0.27 -0.05 (-15.64%) As of 09:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Silexion Therapeutics Stock (NASDAQ:SLXN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$0.26▼$0.2650-Day Range$0.32▼$2.7852-Week Range$0.26▼$42.60Volume842,915 shsAverage Volume1.72 million shsMarket Capitalization$1.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies. Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer. The company has also developed LODER, a localized delivery platform intended to release siRNA directly within a tumor. These programs have primarily been evaluated for pancreatic ductal adenocarcinoma, with the broader goal of addressing KRAS-driven solid tumors. The company traces its origins to an Israeli biotechnology operation focused on localized RNA-interference therapies and became publicly traded on Nasdaq through a business combination in 2024. Silexion’s activities are primarily focused on research and clinical development, and its drug candidates remain investigational rather than commercially approved products.AI Generated. May Contain Errors. Read More Silexion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSLXN MarketRank™: Silexion Therapeutics scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingSilexion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageSilexion Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Silexion Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Silexion Therapeutics are expected to grow in the coming year, from ($4.70) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silexion Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilexion Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silexion Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of Silexion Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilexion Therapeutics has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silexion Therapeutics has recently decreased by 87.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilexion Therapeutics does not currently pay a dividend.Dividend GrowthSilexion Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentSilexion Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Silexion Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for SLXN on MarketBeat in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silexion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.77% of the stock of Silexion Therapeutics is held by insiders.Percentage Held by Institutions10.95% of the stock of Silexion Therapeutics is held by institutions.Read more about Silexion Therapeutics' insider trading history. Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLXN Stock News HeadlinesBrokers Issue Forecasts for SLXN FY2027 EarningsSeptember 22 at 7:29 AM | americanbankingnews.com5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & IndaptusSeptember 10, 2026 | rttnews.comHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its valuation has doubled since the announcement, with some estimates putting the company's worth near 3 trillion dollars by IPO day. Google, Amazon, Nvidia and Microsoft have all taken stakes, while Goldman Sachs, Morgan Stanley and JPMorgan are competing for private shares. Anthropic's annualized revenue reportedly grew 80 times in the first quarter alone. See how investors are positioning ahead of this closely watched IPO.September 24 at 1:00 AM | Weiss Ratings (Ad)Silexion Therapeutics to Participate in September 2026 Industry and Investor ConferencesSeptember 9, 2026 | globenewswire.comSilexion Posts Wider Q2 Loss On Higher SIL-204 Development CostsSeptember 4, 2026 | rttnews.comAfter Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)August 25, 2026 | markets.businessinsider.comSilexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comSilexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-BellAugust 12, 2026 | finance.yahoo.comSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $19.20 at the start of the year. Since then, SLXN shares have decreased by 98.4% and is now trading at $0.3153. How were Silexion Therapeutics' earnings last quarter? Silexion Therapeutics Corp (NASDAQ:SLXN) released its earnings results on Saturday, August, 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($21.20) by $16.03. When did Silexion Therapeutics' stock split? Silexion Therapeutics shares reverse split before market open on Sunday, July 27th 2025.The 1-15 reverse split was announced on Sunday, July 27th 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Silexion Therapeutics' major shareholders? Top institutional investors of Silexion Therapeutics include Ancora Advisors LLC (7.14%). How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings8/15/2026Today9/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SLXN's financial health is in the Red zone, according to TradeSmith. SLXN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLXN Previous SymbolNASDAQ:SLXN CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395Employees14Year Founded2024Profitability EPS (Trailing Twelve Months)($42.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-563.11% Return on Assets-201.73% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book0.03Miscellaneous Outstanding Shares5,560,000Free Float5,517,000Market Cap$1.48 million OptionableN/A Beta-0.36 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SLXN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLXN Stock Alerts